Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal diseases, has appointed Aaron Osborne, MBBS, as Chief Medical Officer and Chief Development Officer. He is joined by recent hires Anil Lalwani, MS, MBA, Vice President of CMC and Quality, and Jared Stephens, PhD, Vice President of Strategy and BD.
 
“We are excited to welcome these experienced biopharmaceutical executives,” said Sulagna Bhattacharya, Nanoscope CEO. “They will play integral roles in developing our optogenetic gene therapies to restore vision in millions of people blinded by retinal diseases.”
 
Dr. Osborne has more than 20 years of experience in ophthalmology. Most recently, he served as Chief Medical Officer at Adverum and previously held clinical development and medical affairs roles of increasing responsibility at Genentech, Alcon, Novartis and Bayer. 
 
Mr. Lalwani joined the company from AbbVie and has 25 years of experience in CMC, quality and regulatory affairs in the biopharmaceutical industry. 
 
Dr. Stephens leads strategy and business development for Nanoscope Therapeutics. Prior to joining Nanoscope, he served as Director of Strategy, Search & Evaluation for GE Healthcare and leadership roles at Absci and Bionano.